Sun Pharmaceuticals' shares fell by 3.62% after a US court blocked its launch of Leqselvi until further legal developments or the expiry of a key patent. Sun Pharma plans to appeal the decision. Analysts suggest a potential appeal or settlement to expedite the product launch, with minimal impact if delayed until 2026.
